Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

NIH 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Prostatic Neoplasms 56Lung Neoplasms 48Leukemia, Myeloid, Acute 44Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 36Myelodysplastic Syndromes 27Pancreatic Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Multiple Myeloma 23Colorectal Neoplasms 23Carcinoma, Renal Cell 22Neoplasm Metastasis 20Melanoma 19Glioblastoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Ovarian Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Brain Neoplasms 16Triple Negative Breast Neoplasms 14Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Hepatocellular 12Lymphoma, Mantle-Cell 11Lymphoma, B-Cell 11Leukemia, Myelomonocytic, Chronic 11Fallopian Tube Neoplasms 11Rectal Neoplasms 10Myeloproliferative Disorders 10Lymphoma, Follicular 10Colonic Neoplasms 10Hematopoietic and Lymphatic System Neoplasm 9

Interventions

Cisplatin 104Radiotherapy, Intensity-Modulated 59Gemcitabine 53toripalimab 35Fluorouracil 30Docetaxel 30Capecitabine 28Radiotherapy 23Drug Therapy 20camrelizumab 19nimotuzumab 16nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11spartalizumab 10endostar protein 8Paclitaxel 8Cetuximab 8tislelizumab 7pembrolizumab 7Endostatins 7Bevacizumab 7anlotinib 6Radiation 6Endoscopy 6fludarabine 5S 1 (combination) 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Nasopharyngeal Carcinoma × Specimen Handling × Clear all
NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

Phase 2 Recruiting
98 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

Phase 1 Recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT06636734 2026-02-11

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Emory University

Phase 2 Recruiting
28 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡